Safe Switch to an Oral Two‐Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV‐1: An Observational Multicenter Study

ABSTRACT Background and Aims People with vertically acquired HIV‐1 are exposed to antiretroviral drugs throughout their lives. Two‐drug regimens based on dolutegravir (DTG) are increasingly popular, showing excellent safety and efficacy and giving the opportunity to reduce toxicity and drug burden....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Health science reports Ročník 8; číslo 7; s. e71047 - n/a
Hlavní autoři: Meraviglia, Giulia, Sala, Anna, Bassani, Francesco, Labate, Laura, Pagani, Gabriele, Giacomet, Vania, Di Biagio, Antonio, Rusconi, Stefano
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States John Wiley & Sons, Inc 01.07.2025
John Wiley and Sons Inc
Wiley
Témata:
Antiretroviral drugs
Cholesterol
dolutegravir
Drug dosages
Drug interactions
Drug resistance
Drug therapy
Environmental Health
High density lipoprotein
HIV
Human immunodeficiency virus
Infections
Infectious Diseases
Low density lipoprotein
Lymphocytes
Mutation
Obstetrics/Gynecology
Paediatrics and Adolescent Medicine
Protease inhibitors
Research Communication
Toxicity
treatment‐experienced
Triglycerides
two‐drug regimen
vertical HIV
treatment‐experienced
dolutegravir
drug resistance
vertical HIV
two‐drug regimen
ISSN:2398-8835, 2398-8835
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:ABSTRACT Background and Aims People with vertically acquired HIV‐1 are exposed to antiretroviral drugs throughout their lives. Two‐drug regimens based on dolutegravir (DTG) are increasingly popular, showing excellent safety and efficacy and giving the opportunity to reduce toxicity and drug burden. However, studies reporting experience in this special population are still lacking. With this study, we evaluated the efficacy and safety of a switch to a two‐drug regimen based on DTG in young people with vertically acquired HIV‐1 infection. Methods This retrospective, multicenter study included subjects with vertically acquired HIV‐1 infection who switched from a combination antiretroviral therapy to a two‐drug regimen with DTG associated with lamivudine, non‐nucleoside reverse transcriptase inhibitors, or boosted protease inhibitors. Results The study included 27 subjects. All of them were virologically suppressed at the moment of the switch except two, with CD4+ lymphocyte T count > 200 cell/mm3. With a median follow‐up of 24.6 months, no virologic failure was detected after the switch except for one patient with poor adherence, and there was no significant difference in CD4+ lymphocyte T count (p = 0.179). Renal function and lipid profile were not influenced by the switch. No side effects have been reported. Conclusion Our experience supports the switch to a two‐drug regimen based on DTG for people with vertically acquired HIV‐1, being safe and effective in maintaining virologic suppression and an adequate CD4+ lymphocyte T count.
Bibliografie:Antonio Di Biagio and Stefano Rusconi are co‐last authors.
Giulia Meraviglia and Anna Sala are co‐first authors.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2398-8835
2398-8835
DOI:10.1002/hsr2.71047